An Open-label Single-arm Single-dose Prospective Multicenter Phase 2b Study to Establish Image Interpretation Criteria for 18F-Fluciclovine Positron Emission Tomography (PET) in Detecting Recurrent Brain Metastases after Radiation Therapy (PURSUE)
Brief description of study
The purpose of the study is to establish visual image interpretation criteria and safety for 18F-fluciclovine Positron Emission Tomography (PET) in detecting recurrent brain metastases. The investigational product in this study is 18F-Fluciclovine injection, which means that it has not been approved by the U.S Food and Drug Administration (FDA), the health authority that gives approval for new medicines to be prescribed in the United States, but the FDA has given its permission to test this agent in the current trial.
Clinical Study Identifier: s20-01326
ClinicalTrials.gov Identifier: NCT04410367
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
